|
|
|
| 替雷利珠单抗联合阿昔替尼治疗转移性肾癌1例 |
| 赵文磊1,2, 黄燕1, 王涛1,2, 张祥义1, 马鑫1, 张旭1 |
1中国人民解放军总医院泌尿外科学部 100853 北京;
2解放军医学院 |
|
| Adjuvant Tislelizumab and Axitinib in Metastatic Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Case Report |
| ZHAO Wenlei1,2, HUANG Yan1, WANG Tao1,2, ZHANG Xiangyi1, MA Xin1, ZHANG Xu1 |
1Department of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing 100853, China;
2Medical School of Chinese PLA |
| 引用本文: |
赵文磊, 黄燕, 王涛, 张祥义, 马鑫, 张旭. 替雷利珠单抗联合阿昔替尼治疗转移性肾癌1例[J]. 微创泌尿外科杂志, 2021, 10(6): 418-420.
ZHAO Wenlei, HUANG Yan, WANG Tao, ZHANG Xiangyi, MA Xin, ZHANG Xu. Adjuvant Tislelizumab and Axitinib in Metastatic Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Case Report. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2021, 10(6): 418-420.
|
|
|
|
| 链接本文: |
| http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1726.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2021/V10/I6/418 |
[1] HWANG JK, AGARWAL N, BRUGAROLAS J, et al.Checking the hippo in sarcomatoid renal cell carcinoma with immunotherapy. Clin Cancer Res, 2021,27(1):5-7.
[2] ZHANG L, WU B, ZHA Z, et al.The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis. Cancer Manag Res, 2018,10:1687-1703.
[3] MOLINA AM, TICKOO SK, ISHILL N, et al.Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol, 2011,34(5):454-459.
[4] RINI B, MOTZER RJ, POWLES T, et al.Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. Eur Urol, 2021,79(5):659-662.
[5] SHUCH B, AMIN A, ARMSTRONG AJ, et al.Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol, 2015,67(1):85-97.
[6] MOTZER RJ, PENKOV K, HAANEN J, et al.Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 2019,380(12):1103-1115.
[7] RINI BI, PLIMACK ER, STUS V, et al.Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 2019,380(12):1116-1127.
[8] SHEN L, GUO J, ZHANG Q, et al.Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J Immunother Cancer, 2020,8(1):e000437.
[9] MORI K, ABUFARAJ M, MOSTAFAEI H, et al.The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors:a systematic review and meta-analysis. Eur Urol, 2021,79(6):783-792.
[10] REBUZZI SE, PERRONE F, BERSANELLI M, et al.Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Mol Diagn, 2020,20(2):169-185.
[11] CHOUEIRI TK, ALBIGES L, HAANEN J, et al.Biomarker analyses from JAVELIN Renal 101: Avelumab+axitinib(A+Ax)versus sunitinib(S)in advanced renal cell carcinoma(aRCC). J Clini Oncol, 2019,37(15_suppl):101.
[12] MOTZER RJ, RINI B, MCDERMOTT DF, et al.Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol, 2019,20(10):1370-1385.
[13] MCDERMOTT DF, HUSENI MA, ATKINS MB, et al.Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med, 2018,24(6):749-757.
[14] MIAN BM, BHADKAMKAR N, SLATON JW, et al.Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol, 2002,167(1):65-70.
[15] DE PERALTA-VENTURINA M, MOCH H, AMIN M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol, 2001,25(3):275-284. |
|
|
|
